Patch

New York, United States Founded: 2020 • Age: 6 yrs Acquired By Ginkgo Bioworks
Gene therapies for a broad range of diseases are developed.
Annual revenue - Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors 1 Known backers
Products - Services tracked
Competitors 10 Brand Intelligence

About Patch

Patch is a company based in New York (United States) founded in 2020 was acquired by Ginkgo Bioworks in February 2024. Patch operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.

  • Headquarter New York, United States
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    Not available
  • Investors
  • Employee Count
    Not available
  • Acquired by
    Ginkgo Bioworks

    (Feb 28, 2024)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Patch

Premium access

Detailed funding history for Patch

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investors in Patch

Patch has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Ginkgo Bioworks.

All
Institutional
Investor Description Founded Year Domain Location
Gene editing-based cultured ingredients are provided for agriculture.
Locked Locked Locked
Premium access

Investor details for Patch

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Patch

Investments
Premium access

Investment portfolio details for Patch

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Patch

Premium access

Detailed financials for Patch

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Patch Comparisons

Patch Primary company
Description
Gene therapies for a broad range of diseases are developed.
Location
New York, United States
Founded Year
2020
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Patch

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Patch

Patch operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Therapeutics for genetic diseases are developed through targeted interventions.
Locked Locked Locked
Gene therapies for rare diseases including retinal dystrophies are developed.
Locked Locked Locked
RNA interference-based therapeutics are developed for multiple disorders.
Locked Locked Locked
A biopharmaceutical company accelerating innovative mental health treatments.
Locked Locked Locked
An AI-enabled platform is developed for infectious disease treatment.
Locked Locked Locked
Therapeutics for rare and ultra-rare metabolic diseases are developed.
Premium access

Detailed competitors of Patch

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Patch

Premium access

Complete news archive for Patch

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Patch

Patch was founded in 2020.

Patch is headquartered in New York, United States. It is registered at New York, New York, United States.

Founded in 2020 and based in New York, United States, Patch operates in the biotechnology sector. Gene therapies are engineered to address various disease conditions through a platform that incorporates large-scale DNA synthesis and machine learning. This approach supports the creation of targeted treatments for multiple health challenges, with ongoing development focused on scalability and precision in therapeutic applications.

Patch's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.

Patch has 1 investor. Key investors include Ginkgo Bioworks.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available